FDG PET and PET/CT in the Management of Pediatric Lymphoma Patients.

[1]  A. Zytoon,et al.  Positron emission tomography and breast lesions: low FDG activity in early phase imaging is not essentially benign. , 2008, Clinical nuclear medicine.

[2]  W. Liu,et al.  Comparison of gallium and PET scans at diagnosis and follow‐up of pediatric patients with Hodgkin lymphoma , 2008, Pediatric blood & cancer.

[3]  G. Bisi,et al.  FDG-PET in the detection of bone marrow disease in Hodgkin's disease and aggressive non-Hodgkin's lymphoma and its impact on clinical management. , 2008, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....

[4]  R. Wahl,et al.  FDG PET and risk-adapted therapy in Hodgkin's and non-Hodgkin's lymphoma , 2008, Current opinion in oncology.

[5]  H. Schöder,et al.  PET imaging for response assessment in lymphoma: potential and limitations. , 2008, Radiologic clinics of North America.

[6]  S. de Vos,et al.  The impact of fluorodeoxyglucose-positron emission tomography in primary staging and patient management in lymphoma patients. , 2008, Radiologic clinics of North America.

[7]  A. Shaw,et al.  Response assessment in lymphoma. , 2008, Clinical radiology.

[8]  J. Sweetenham.  Minimizing late effects in children and adults with Hodgkin lymphoma – The beginning of the end for radiation therapy , 2008, Leukemia & lymphoma.

[9]  T. Nihashi,et al.  18F-FDG PET for Posttherapy Assessment of Hodgkin's Disease and Aggressive Non-Hodgkin's Lymphoma: A Systematic Review , 2007, Journal of Nuclear Medicine.

[10]  B. Cheson,et al.  The role of FDG-PET scans in patients with lymphoma. , 2007, Blood.

[11]  A. Kirby,et al.  The role of FDG PET in the management of lymphoma: what is the evidence base? , 2007, Nuclear medicine communications.

[12]  Z. Keidar,et al.  The incremental value of 18F-FDG PET/CT in paediatric malignancies , 2007, European Journal of Nuclear Medicine and Molecular Imaging.

[13]  C. Minniti,et al.  Utility of PET scans to predict disease relapse in pediatric patients with Hodgkin lymphoma , 2007, Pediatric blood & cancer.

[14]  R. Hicks,et al.  Overview of early response assessment in lymphoma with FDG-PET , 2007, Cancer imaging : the official publication of the International Cancer Imaging Society.

[15]  Sigrid Stroobants,et al.  Revised response criteria for malignant lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  Klemens Scheidhauer,et al.  Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  A. Alavi,et al.  Dual-Time Point FDG PET Imaging in the Evaluation of Pulmonary Nodules With Minimally Increased Metabolic Activity , 2007, Clinical nuclear medicine.

[18]  H. Brisse,et al.  Prospective study of 18F-FDG PET in pediatric mediastinal lymphoma: A single center experience , 2007, Leukemia & lymphoma.

[19]  K. Frey,et al.  Comparison of 18F Flurodeoxyglucose PET with Ga-67 scintigraphy and conventional imaging modalities in pediatric lymphoma , 2007, Leukemia & lymphoma.

[20]  K. Kelly,et al.  Routine Use of PET Scans After Completion of Therapy in Pediatric Hodgkin Disease Results in a High False Positive Rate , 2006, Journal of pediatric hematology/oncology.

[21]  J. Coya,et al.  PET/CT in lymphoma: prospective study of enhanced full-dose PET/CT versus unenhanced low-dose PET/CT. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[22]  I. Steffen,et al.  Correlative Imaging Strategies Implementing CT, MRI, and PET for Staging of Childhood Hodgkin Disease , 2006, Journal of pediatric hematology/oncology.

[23]  F. Valette,et al.  FDG-PET/CT predicts outcome in patients with aggressive non-Hodgkin’s lymphoma and Hodgkin’s disease , 2006, Annals of Hematology.

[24]  Ur Metser,et al.  Role of 18F-FDG PET/CT in Staging and Follow-up of Lymphoma in Pediatric and Young Adult Patients , 2006, Journal of computer assisted tomography.

[25]  W. Martin,et al.  Utility of FDG-PET/CT in Follow-Up of Children Treated for Hodgkin and Non-Hodgkin Lymphoma , 2006, Journal of pediatric hematology/oncology.

[26]  A. Nasr,et al.  Assessment of residual posttreatment masses in Hodgkin's disease and the need for biopsy in children. , 2006, Journal of pediatric surgery.

[27]  A. Alavi,et al.  F-18 FDG-PET imaging and correlation with CT in staging and follow-up of pediatric lymphomas , 2006, Pediatric Radiology.

[28]  R. Kodet,et al.  Comparison of 18F-FDG-PET and standard procedures for the pretreatment staging of children and adolescents with Hodgkin’s disease , 2006, European Journal of Nuclear Medicine and Molecular Imaging.

[29]  Abass Alavi,et al.  Can [18F]fluorodeoxyglucose positron emission tomography imaging complement biopsy results from the iliac crest for the detection of bone marrow involvement in patients with malignant lymphoma? , 2006, Nuclear medicine communications.

[30]  Yuji Nakamoto,et al.  Direct comparison of FDG PET and CT findings in patients with lymphoma: initial experience. , 2005, Radiology.

[31]  H. Amthauer,et al.  FDG-PET in 10 children with Non-Hodgkin’s Lymphoma: Initial Experience in Staging and Follow-up , 2005, Klinische Padiatrie.

[32]  Emmanuel Itti,et al.  [18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. , 2005, Blood.

[33]  R. Hustinx,et al.  Evaluation of therapy for lymphoma. , 2005, Seminars in nuclear medicine.

[34]  M. M. Mac Manus,et al.  Initial staging of lymphoma with positron emission tomography and computed tomography. , 2005, Seminars in nuclear medicine.

[35]  H. Kiat,et al.  Direct comparison of 18F‐fluorodeoxyglucose coincidence gamma camera tomography with gallium scanning for the staging of lymphoma , 2005, Internal medicine journal.

[36]  W. Heindel,et al.  Staging in childhood lymphoma: differences between FDG-PET and CT. , 2005, Nuklearmedizin. Nuclear medicine.

[37]  K. Nichols,et al.  Coincidence-detection FDG-PET versus gallium in children and young adults with newly diagnosed Hodgkin’s disease , 2005, Pediatric Radiology.

[38]  Osman Ratib,et al.  Comparison between 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography and positron emission tomography/computed tomography hardware fusion for staging of patients with lymphoma. , 2004, Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging.

[39]  S. Reske,et al.  [18F]3'-deoxy-3'-fluorothymidine-PET in NHL patients: whole-body biodistribution and imaging of lymphoma manifestations--a pilot study. , 2004, Cancer biotherapy & radiopharmaceuticals.

[40]  S. Berlangieri,et al.  Positron emission tomography scanning in the assessment of patients with lymphoma , 2004, Internal medicine journal.

[41]  R. Pötter,et al.  The Concept of the GPOH-HD 2003 Therapy Study for Pediatric Hodgkin's Disease: Evolution in the Tradition of the DAL/GPOH Studies , 2004, Klinische Padiatrie.

[42]  T. Yen,et al.  Restaging of recurrent cervical carcinoma with dual‐phase [18F]fluoro‐2‐deoxy‐D‐glucose positron emission tomography , 2004, Cancer.

[43]  P. Sinha,et al.  Narrow time-window dual-point 18F-FDG PET for the diagnosis of thoracic malignancy , 2003, Nuclear medicine communications.

[44]  D. Hasenclever,et al.  Importance of F18-Fluorodeoxy-D-2-Glucose Positron Emission Tomography (FDG-PET) for Staging and Therapy Control of Hodgkin’s Lymphoma in Childhood and Adolescence – Consequences for the GPOH-HD 2003 Protocol , 2003, Oncology Research and Treatment.

[45]  G. Leverger,et al.  [18F]FDG in childhood lymphoma: clinical utility and impact on management , 2002, European Journal of Nuclear Medicine and Molecular Imaging.

[46]  C D Claussen,et al.  Comparison of 18FDG-PET with CT scans in the evaluation of patients with residual and recurrent Hodgkin's lymphoma. , 2001, Oncology reports.

[47]  A. Alavi,et al.  Dual time point 18F-FDG PET imaging for differentiating malignant from inflammatory processes. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[48]  Hiroshi Fukuda,et al.  Advantage of delayed whole-body FDG-PET imaging for tumour detection , 2001, European Journal of Nuclear Medicine.

[49]  H. Schirrmeister,et al.  2‐(fluorine‐18)fluoro‐2‐deoxy‐D‐glucose positron emission tomography in the detection and staging of malignant lymphoma , 2001, Cancer.

[50]  J. Armitage,et al.  A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. , 1998, The New England journal of medicine.

[51]  J. D. van der Walt,et al.  Detection of lymphoma in bone marrow by whole-body positron emission tomography. , 1998, Blood.

[52]  E. Merkle,et al.  Extranodal malignant lymphoma: detection with FDG PET versus CT. , 1998, Radiology.

[53]  Emili Montserrat,et al.  A predictive model for aggressive non-Hodgkin's lymphoma. , 1993, The New England journal of medicine.

[54]  E. Anderson.  Hudson et al. , 1977 .

[55]  R. Tiling,et al.  Restaging of patients with lymphoma , 2008, Nuklearmedizin.

[56]  R. Wahl,et al.  Integrating PET and PET/CT into the risk-adapted therapy of lymphoma. , 2007, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[57]  Lotty Hooft,et al.  18F-fluoro-deoxyglucose positron emission tomography for post-treatment evaluation of malignant lymphoma: a systematic review. , 2006, Haematologica.

[58]  Martin Hutchings,et al.  FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. , 2006, Blood.

[59]  A. Nagler,et al.  Is CT scan still necessary for staging in Hodgkin and non-Hodgkin lymphoma patients in the PET/CT era? , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[60]  R. Hustinx,et al.  18F-FDG PET in children with lymphomas , 2004, European Journal of Nuclear Medicine and Molecular Imaging.